Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement recruitment using bispecific diabodies

R E Kontermann1, M G Wing, G Winter

  • 1MRC Centre for Protein Engineering, Cambridge, UK. rek@imt.uni-marburg.de

Nature Biotechnology
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoliposomes - a new therapeutic option to treat SynGAP1-associated epilepsy.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2025
Same author

Development of a sprayable hydrogel formulation for the skin application of therapeutic antibodies.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2019
Same author

Structure determination and crystal chemistry of large repeat mixed-layer hexaferrites.

IUCrJ·2018
Same author

Letter to the Editor.

Radiography (London, England : 1995)·2017
Same author

Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis.

The Veterinary record·2017
Same author

Testing and clinical implications for non-V600 BRAF mutations in metastatic NRAS<sup>mt</sup> melanoma.

The British journal of dermatology·2016
Same journal

Unlocking the chemical potential of filamentous fungi using prime editing.

Nature biotechnology·2026
Same journal

A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.

Nature biotechnology·2026
Same journal

Prime editing for precise genome engineering and modulation of fungal metabolism.

Nature biotechnology·2026
Same journal

Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.

Nature biotechnology·2026
Same journal

A retargeted recombinase for precise insertion of large DNA.

Nature biotechnology·2026
Same journal

Experiment-guided AlphaFold3 resolves measurement-consistent protein ensembles.

Nature biotechnology·2026
See all related articles

Researchers engineered bispecific antibodies (diabodies) to activate the complement system. These novel antibodies efficiently lyse target cells and enhance immune cell interactions, showing potential for therapeutic complement activation.

Area of Science:

  • Immunology
  • Biotechnology
  • Molecular Engineering

Background:

  • The complement system is crucial for innate immunity.
  • Antibody fragments offer versatile therapeutic platforms.
  • Engineering bispecific antibodies can direct immune responses.

Purpose of the Study:

  • To engineer antibody fragments for bacterial production.
  • To create bispecific antibodies (diabodies) that recruit complement.
  • To evaluate the therapeutic potential of complement-activating diabodies.

Main Methods:

  • Phage display was used to isolate human antibody fragments against complement C1q.
  • Lysozyme-specific antibody fragments were linked to C1q-specific fragments to create diabodies.
  • The functional activity of diabodies was assessed using sheep erythrocytes and human monocytes.

Related Experiment Videos

Main Results:

  • Engineered diabodies successfully recruited complement C1q.
  • Diabodies mediated efficient lysis of target erythrocytes.
  • Diabodies induced erythrocyte-monocyte rosette formation and phagocytosis.

Conclusions:

  • Bispecific diabodies can be produced in bacteria to activate complement.
  • These engineered antibodies demonstrate potential for therapeutic applications involving complement activation.
  • Further development may lead to novel treatments for diseases requiring complement modulation.